Nonalcoholic fatty liver disease in children living in the obeseogenic society

Background The problem of obesity in children has grown considerably in recent years in the United States as well as the rest of the world. This has resulted in a marked increase in the prevalence of nonalcoholic liver disease in the pediatric age group. Nonalcoholic fatty liver disease (NAFLD) is c...

Full description

Saved in:
Bibliographic Details
Published in:World journal of pediatrics : WJP 2009-11, Vol.5 (4), p.245-254
Main Author: Hesham A-Kader, H.
Format: Article
Language:English
Subjects:
Child
Comorbidity
Critical Care Medicine
Disease Progression
Fatty Liver - diagnosis
Fatty Liver - epidemiology
Fatty Liver - physiopathology
Fatty Liver - therapy
Humans
Imaging
Intensive
Liver Cirrhosis - epidemiology
Magnetic Resonance Imaging
Maternal and Child Health
Medicine
Medicine & Public Health
Obesity - epidemiology
Obesity - therapy
Pediatric Surgery
Pediatrics
Prevalence
Radiology
Review Article
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The problem of obesity in children has grown considerably in recent years in the United States as well as the rest of the world. This has resulted in a marked increase in the prevalence of nonalcoholic liver disease in the pediatric age group. Nonalcoholic fatty liver disease (NAFLD) is currently the most common hepatic disorder seen in pediatric hepatology practice. Data sources We have reviewed the most recent literature regarding the prevalence, pathogenesis as well as the most recent advances in the diagnostic and therapeutic modalities of NAFLD in children. Results NAFLD affects a substantial portion of the population including children. Conclusions The rising incidence of NAFLD, nonalcoholic steatohepatitis (NASH) and cirrhosis emphasizes the need for effective treatment options. The lack of complete understanding of the pathogenesis of NAFLD still limits our ability to develop novel therapeutic modalities that can target the metabolic derangements implicated in the development of the disorder.
ISSN:1708-8569
1867-0687
DOI:10.1007/s12519-009-0048-8